Summary & Overview
HCPCS Q2043: Sipuleucel-t Cellular Immunotherapy Infusion
HCPCS Level II code Q2043 designates sipuleucel-t, an autologous cellular immunotherapy delivered as an infusion that includes leukapheresis and all preparatory procedures. This code captures both the personalized cell product and the associated clinical processes, making it relevant to oncology providers, infusion centers, and payers managing high-cost specialty therapies. Nationally, the code is significant because it represents a bundled approach to billing for a complex, site-specific therapy with substantial clinical and financial implications.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical service captured by Q2043, typical sites of care, and which payers are commonly involved in coverage. The publication outlines expected benchmarks and reimbursement context, relevant policy considerations for specialty biologics and cellular therapies, and the clinical context for use of sipuleucel-t in oncology.
The content provides actionable reference material for billing professionals, revenue cycle leaders, and clinical administrators seeking clarity on coding, site-of-service implications, and payer engagement for this therapy. Data not provided in the input — such as specific payment amounts, utilization metrics, and ICD-10 pairings — is noted where applicable as unavailable.
Billing Code Overview
HCPCS Level II code Q2043 represents sipuleucel-t, a personalized cellular immunotherapy consisting of a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, and includes leukapheresis and all preparatory procedures, billed per infusion.
Service Type: Cellular immunotherapy infusion with leukapheresis and preparation services included
Typical Site of Service: Hospital outpatient infusion center or specialized oncology infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 72-year-old man with asymptomatic metastatic castration-resistant prostate cancer (mCRPC) presents to the infusion center for manufacture and infusion of sipuleucel-t. The clinical workflow begins with a referral from the medical oncologist to a leukapheresis-capable infusion center. Baseline evaluation includes review of prior therapies, performance status, and documentation of metastatic disease (often bone-predominant) and castrate-resistant status. The patient undergoes leukapheresis to collect peripheral blood mononuclear cells, which are shipped to the manufacturer for ex vivo activation with PAP-GM-CSF to produce the autologous cellular immunotherapy product. On a scheduled infusion day (typically three infusions at approximately two-week intervals), the patient is pre-assessed by oncology nursing for vital signs and infusion readiness; premedication (acetaminophen and/or antihistamine) is given per protocol. The sipuleucel-t product is thawed and infused intravenously over the recommended time with monitoring for infusion reactions. Documentation includes product lot numbers, cell counts (minimum 50 million CD54+ autologous cells), dates of leukapheresis and infusion, and any acute reactions. Billing uses HCPCS Level II code Q2043 for each infusion and may include appropriate modifiers for place of service, provider attribution, or unusual circumstances. Typical site of service is an outpatient hospital infusion center or freestanding oncology infusion clinic with leukapheresis capability. Typical patient scenario: older male with mCRPC receiving a three-dose individualized immunotherapy series following confirmation of castration resistance and adequate performance status.
Coding Specifications
| Modifier | Description | When to Use |
|---|